The DSMB meets periodically to review the safety results to date (Merck is blind to these data) to be certain that patients on Vytorin are not experiencing any unexpected safety issues.

FORBES: Cholesterol Drug Heart Study Continues, But Will Merck's Vytorin Really IMPROVE-IT?

Consider seeking a relationship with a financial professional, either on going or from time to time, to not only point out areas that are blind spots, but also to establish deadlines for implementation and review.

FORBES: New Study Finds Those Who Are Not Under Financial Stress Will Be Soon